04 September 2018
A new report by visiongain forecasts that sales of endoscopy devices Market Report will reach $42bn in 2020. Revenue growth will continue through to 2026, with rising demand for minimally invasive medical procedures.
That sales prediction and others appear in Endoscopy Systems Industry and Market: Forecasts and Discussions 2016-2026 – Laparoscopy, Urology, Gastrointestinal Uses, Arthroscopy, ENT Endoscopy and Gynaecology, Assessing Technologies Including Enteroscopy, Colonoscopy, Capsule Endoscopy, ERCP, Rhinoscopy, Laryngoscopy, Bronchoscopy, Cystoscopy, Ureteroscopy, Prenatal Applications and Sales in the US, Japan, Germany, France, UK, Italy, Spain, China and India.
The updated study, published in July 2016, analyses events, prospects and opportunities shaping the development, production and marketing of endoscopic devices for medicine. Visiongain’s investigation shows multilevel revenue forecasting and qualitative assessments for those systems in diagnostics and surgery. That work also explores activities of companies providing endoscopy devices, assessing their potentials. The healthcare endoscopy market holds many technological and commercial opportunities from 2016, including rising sales in developed and developing countries.
Market growth is driven by the rising incidence and prevalence of chronic diseases worldwide, which drive demand for new, improved diagnostic and therapeutic endoscopic procedures in developed and emerging national markets.
Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “A key factor in the growth of the medical devices market is endoscopy, which has progressed rapidly in recent years owing primarily to an increased patient demand in minimally invasive procedures for treatment and diagnosis purposes. Technological advances propelled the field of endoscopy, with new and innovative devices offering enhanced image quality and access to regions of the body previously thought as difficult to access.
“The increasingly improving healthcare systems and economic prosperity in the emerging markets will be a main driver of growth within the endoscopy devices market. Furthermore, the rise in incidences of chronic diseases, improvements in technology, awareness of early screening and the demand for minimally invasive procedures will fuel strong demand for endoscopy devices globally.”
Visiongain’s new study gives revenue predictions to 2026 for seven medical endoscopy submarkets at world level:
• Laparoscopy • Urology • Gastrointestinal uses • Arthroscopy • Ear, nose and throat (ENT) endoscopy • Gynaecological uses • Other applications.
That report shows revenue prospects in developed and developing markets, with revenue forecasts to 2026 for nine countries:
• US • Japan • Germany, France, UK, Italy and Spain • China and India.
From 2016, large medical devices companies and other specialists can prosper in that market. Companies discussed include these organisations:
• Karl Storz • Smith and Nephew • Olympus • Stryker • Richard Wolf • Given Imaging • Fujifilm.
Endoscopy Systems Industry and Market: Forecasts and Discussions 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.